Atlas Trials

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Clinical trial NCT03289819 · COMPLETED

Trial details

NCT number
NCT03289819
Sponsor
Institut fuer Frauengesundheit
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Neoplasm of Breast
Start date
2018-03-23
Primary completion
2020-08-27
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.